Ingmar de GooijerImproving the odds of the drug development lotteryThere’s a societal debate raging across the globe about the unaffordability of new drugs and it’s becoming more polarised every day. Blame…Jan 16, 2020Jan 16, 2020
Ingmar de GooijerMaking drugs affordable againIn February last year, the CEOs of the largest pharma and biotech companies were grilled by politicians about the pricing of drugs at a US…Jan 14, 2020Jan 14, 2020
Ingmar de GooijerApproval and funding mechanisms for new drugs are not fit for purpose anymore.Calls for more transparency, HTA and value-based pricing are counterproductiveJan 10, 2020Jan 10, 2020